- Trial phase
- Phase 1/1b/2
- Time to market
- OP-3136 is in Phase 1/1b/2 clinical trials. If development proceeds successfully, a potential approval would likely be several years away, contingent on completing Phase 2/3 trials.
- Why 4/10
- The next hard, dated catalyst for OP-3136 is the presentation of combination data from the palazestrant and OP-3136 programs at the San Antonio Breast Cancer Symposium (SABCS) in December 2026. This is a scientific conference presentation of early-stage data, not a pivotal readout or regulatory decision. OP-3136 is a Phase 1/1b/2 pipeline asset behind Olema's lead drug palazestrant (Phase 3), so even positive SABCS data would be a modest catalyst for the stock. ImpactScore is 4.
The next catalyst for OP-3136 is the SABCS presentation in December 2026, where combination data with palazestrant will be shown. Positive data could support the combination strategy and boost confidence in the broader pipeline, but the stock's primary near-term binary is the Phase 3 OPERA-01 palazestrant readout expected in Q1 2027. OP-3136 remains an early-stage pipeline asset, and its data at SABCS is unlikely to be a standalone stock-moving event.
Price Chart
Executive Summary
OP-3136 is an oral KAT6 inhibitor in Phase 1/1b/2 development by Olema Pharmaceuticals (Nasdaq: OLMA) for breast cancer and potentially other solid tumors. Initial Phase 1 monotherapy data presented at ASCO in May 2026 showed a clean safety profile (no dose-limiting toxicities, no treatment-related discontinuations) and tumor shrinkage in nearly two-thirds of evaluable patients across multiple cancer types. A Phase 1b/2 combination study with palazestrant (Olema's lead SERD/CERAN) is enrolling, and a collaboration with Bayer was signed to test OP-3136 with darolutamide in prostate cancer. The next catalyst is a combination data presentation at the San Antonio Breast Cancer Symposium in December 2026. However, OP-3136 is an early-stage pipeline asset; Olema's primary near-term value driver is the Phase 3 OPERA-01 palazestrant readout expected in Q1 2027.
How It Works
OP-3136 is an oral small-molecule drug that inhibits KAT6, an enzyme involved in epigenetic regulation (chemical modifications that turn genes on or off without changing the DNA sequence). KAT6 is overactive in breast cancer and other solid tumors, driving cancer growth. By blocking KAT6, OP-3136 aims to slow or stop tumor growth. It is being studied alone and in combination with other cancer drugs.
Trial Status
Phase 1 monotherapy dose-escalation study has completed with initial data presented at ASCO June 2026. A Phase 1b/2 study evaluating OP-3136 in combination with fulvestrant and palazestrant is actively enrolling patients. A separate Phase 1b study in combination with Bayer's darolutamide for metastatic castration-resistant prostate cancer is expected to initiate in H2 2026.
The Two-Sided Case
Upcoming Catalysts
- December 2026: Presentation of combination data from the palazestrant and OP-3136 programs at the San Antonio Breast Cancer Symposium (SABCS)
- H2 2026: Initiation of Phase 1b study of OP-3136 in combination with darolutamide for prostate cancer (Bayer collaboration)
- Ongoing: Enrollment and future data readouts from the Phase 1b/2 combination study with palazestrant
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Olema Oncology PRESS-RELEASE OLMA ·Originating report